716-11-0

Basic information

• Product Name: N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE
• Synonyms: 1-(4-Methylquinazolin-2-yl)guanidine;2-(4-methyl-2-quinazolinyl)guanidine;2-(4-methylquinazolin-2-yl)guanidine
• CAS NO: 716-11-0
• Molecular Formula: C₁₀H₁₁N₅
• Molecular Weight: 201.23
• Mol File: 716-11-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 467.6°C at 760 mmHg
• Flash Point: 236.6°C
• Appearance: /
• Density: 1.4g/cm³
• Vapor Pressure: 6.43E-09mmHg at 25°C
• Refractive Index: 1.715
• CAS DataBase Reference: N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE(716-11-0)
• EPA Substance Registry System: N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE(716-11-0)

Safety Data

• Hazardous Substances Data: 716-11-0(Hazardous Substances Data)

Usage

Description

N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE is a chemical compound with the molecular formula C10H9N5. It is a guanidine derivative that contains a quinazoline ring structure and a methyl substituent. N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE has been studied for its potential medicinal properties, particularly as a potential drug for the treatment of various diseases. It has been shown to have inhibitory effects on certain enzymes and receptors, and has been investigated as a potential antiviral and anti-inflammatory agent. Further research is needed to fully understand the biological activities and potential therapeutic applications of N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE.

Uses

Used in Pharmaceutical Industry:
N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE is used as a potential drug candidate for the treatment of various diseases due to its inhibitory effects on certain enzymes and receptors.
Used in Antiviral Applications:
N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE is used as a potential antiviral agent, as it has been shown to have inhibitory effects on certain viral enzymes and receptors.
Used in Anti-Inflammatory Applications:
N-(4-METHYLQUINAZOLIN-2-YL)GUANIDINE is used as a potential anti-inflammatory agent, as it has been investigated for its ability to modulate inflammatory processes and reduce inflammation in the body.

InChI:InChI=1/C10H11N5/c1-6-7-4-2-3-5-8(7)14-10(13-6)15-9(11)12/h2-5H,1H3,(H4,11,12,13,14,15)

Upstream product

• 25384-14-9 2-aminoacetophenone hydrochloride 
• 127099-85-8 N-Cyanoguanidine 
• 54789-74-1 (4-methyl-quinazolin-2-yl)-carbamonitrile 
• 127099-85-8 dicyandiamide 
• 147-47-7 2,2,4-trimethyl-1,2-dihydroquinoline 

Downstream Products

• 263746-95-8 2-((4-methylquinazolin-2-yl)amino)quinazolin-4(1H)-one 

Relevant articles and documents

COMPOUNDS TARGETING DUAL G-QUADRUPLEX DNA AND STAT3

The present invention relates to novel quinazoline compounds having the formula (I) or (II): (I) (II). The compounds are active both as stabilizers of G-quadruplex DNA structures and as inhibitors of STAT3 phosphorylation. The disclosed compounds are useful in medical treatment, such as the treatment of cancer.

Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure

The heme enzyme myeloperoxidase (MPO) participates in innate immune defense mechanism through formation of microbicidal reactive oxidants. However, evidence has emerged that MPO-derived oxidants contribute to propagation of inflammatory diseases. Because of the deleterious effects of circulating MPO, there is a great interest in the development of new efficient and specific inhibitors. Here, we have performed a novel virtual screening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtual screening. Starting from a set of 727842 compounds, 28 molecules were selected by this virtual method and tested on MPO in vitro. Twelve out of 28 compounds were found to have an IC50 less than 5 μM. The best inhibitors were 2-(7-methoxy-4-methylquinazolin-2-yl)guanidine (28) and (R)-2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo[d]imidazole (42) with IC50 values of 44 and 50 nM, respectively. Studies on the mechanism of inhibition suggest that 28 is the first potent mechanism-based inhibitor and inhibits irreversibly MPO at nanomolar concentration.

Compounds for the treatment of pain

This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.